Jennifer English
Director of Contracts and Pricing


What are your key priorities in the next 6-12 months?
Prepare for product launch in new therapeutic area to our company; submit FSS solicitation renewal documents; implement any changes to GP methodology pending Final Rule being published.


How do you feel that the pharmaceutical pricing landscape is evolving, and how does this impact your role?  
Increasing co-insurance and patient annual deductibles are changing the Managed Care landscape and patient out of pocket dynamics. Even having formulary access can still be a costly scenario to a patient’s wallet. ACA expansion of Medicaid and covered population is showing some expansion in Rx already, need to track trends closely for Gross-to-Net projections.


What has been your greatest achievement or most exciting project in your current role?  
I am new to the role, and have successfully completed several contract proposal analyses and bid submissions in a short time frame, as well as provided recommendations for pricing strategy that have been implemented.


What are you most looking forward to about the upcoming Pharmaceutical Pricing & Contracting Conference?
Getting a sense of what other manufacturers are seeing with the advent of the HCX marketplaces and if there is any paradigm shift in payer controls/cost sharing, as well as impact on prescribing physicians in dealing with the changing payer marketplace.


Jennifer will be one of the distinguished speakers at the Pharmaceutical Pricing & Contracting Conference.